Pharmacokinetics of new oral hepatitis C antiviral drugs

50 BOCEPREVIR PLUS PEGINTERFERON/RIBAVIRIN FOR THE TREATMENT OF HCV/HIV CO-INFECTED PATIENTS: END OF TREATMENT (WEEK 48) INTERIM RESULTS

(2012) J. Mallolas et al.   JOURNAL OF HEPATOLOGY

1101 THE EFFECT OF RENAL IMPAIRMENT AND END STAGE RENAL DISEASE ON THE SINGLE-DOSE PHARMACOKINETICS OF PSI-7977

(2012) M.T. Cornpropst et al.   JOURNAL OF HEPATOLOGY

Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1

(2012) Anna S. Lok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Challenges and opportunities for hepatitis C drug development in HIV–hepatitis C virus-co-infected patients

(2011) Vincent Soriano et al.   AIDS

New 2011 updated DHHS antiretroviral treatment guidelines and chronic hepatitis B

(2011) Vincent Soriano et al.   AIDS

Effect of the Hepatitis C Virus Protease Inhibitor Telaprevir on the Pharmacokinetics of Amlodipine and Atorvastatin

(2011) Jee Eun Lee et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus

(2011) Varun Garg et al.   HEPATOLOGY

Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1

(2011) Richard E. Nettles et al.   HEPATOLOGY

The effects of NS5A inhibitors on NS5A phosphorylation, polyprotein processing and localization

(2011) D. Qiu et al.   JOURNAL OF GENERAL VIROLOGY

1244 THE PHARMACOKINETIC INTERACTION BETWEEN METHADONE AND THE INVESTIGATIONAL HCV PROTEASE INHIBITOR TELAPREVIR

(2011) R. van Heeswijk et al.   JOURNAL OF HEPATOLOGY

472 PHARMACOKINETICS OF TMC435 IN SUBJECTS WITH MODERATE HEPATIC IMPAIRMENT

(2011) V. Sekar et al.   JOURNAL OF HEPATOLOGY

60 SILEN-C1: SUSTAINED VIROLOGIC RESPONSE (SVR) AND SAFETY OF BI201335 COMBINED WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN (P/R) IN TREATMENT-NAIVE PATIENTS WITH CHRONIC GENOTYPE 1 HCV INFECTION

(2011) M.S. Sulkowski et al.   JOURNAL OF HEPATOLOGY

61 ONCE DAILY PSI-7977 PLUS PEGIFN/RBV IN A PHASE 2B TRIAL: RAPID VIROLOGIC SUPPRESSION IN TREATMENT-NAIVE PATIENTS WITH HCV GT2/GT3

(2011) J. Lalezari et al.   JOURNAL OF HEPATOLOGY

EASL Clinical Practice Guidelines: Management of hepatitis C virus infection

(2011)   JOURNAL OF HEPATOLOGY

Distinct Functions of NS5A in Hepatitis C Virus RNA Replication Uncovered by Studies with the NS5A Inhibitor BMS-790052

(2011) R. A. Fridell et al.   JOURNAL OF VIROLOGY

Directly acting antivirals for hepatitis C and antiretrovirals

(2011) Kay Seden et al.   Current Opinion in HIV and AIDS

Preclinical Characterization of BI 201335, a C-Terminal Carboxylic Acid Inhibitor of the Hepatitis C Virus NS3-NS4A Protease

(2010) P. W. White et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Telaprevir Is Effective Given Every 8 or 12 Hours With Ribavirin and Peginterferon Alfa-2a or -2b to Patients With Chronic Hepatitis C

(2010) Patrick Marcellin et al.   GASTROENTEROLOGY

Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection

(2010) Michael P. Manns et al.   JOURNAL OF HEPATOLOGY

Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect

(2010) Min Gao et al.   NATURE

In Vitro Activity and Preclinical Profile of TMC435350, a Potent Hepatitis C Virus Protease Inhibitor

(2009) T.-I Lin et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Rapid HCV-RNA Decline With Once Daily TMC435: A Phase I Study in Healthy Volunteers and Hepatitis C Patients

(2009) Henk W. Reesink et al.   GASTROENTEROLOGY

Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection

(2009) John G. McHutchison et al.   NEW ENGLAND JOURNAL OF MEDICINE